Rivaroxaban for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation and Active Cancer
Rivaroxaban is broadly used for the primary prevention of stroke and systemic embolism in the general population with nonvalvular atrial fibrillation (AF). However, there is little published evidence on the safety and efficacy of rivaroxaban for AF in patients with active cancer. The aim of this study was to assess the safety and efficacy of rivaroxaban in patients with active cancer and AF. The use of rivaroxaban in patients with cancer at the Memorial Sloan Kettering Cancer Center is monitored in the setting of a Quality Assessment Initiative.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Eva S. Laube, Anthony Yu, Dipti Gupta, Yimei Miao, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A. Soff, Simon Mantha Tags: Arrhythmias and Conduction Disturbances Source Type: research
More News: Arrhythmia | Atrial Fibrillation | Cancer | Cancer & Oncology | Cardiology | Heart | Stroke | Study